蛇毒纤溶酶Alfimeprase在大肠杆菌中的可溶表达和纯化

Alfimeprase是Fibrolase的突变体,是一种蛇毒纤溶酶,有纤溶活性而无出血性。根据Alfimeprase的氨基酸序列和大肠杆菌密码子偏爱性,利用PCR的方法合成Alfimeprase DNA序列,分别融合在NusA和MBP的C端,与分子伴侣FkpA在大肠杆菌Origami B(DE3)中共表达,融合蛋白NusA/Alfimeprase以部分可溶的形式存在,可溶部分占上清总蛋白的25%左右,通过镍柱亲合层析纯化和肠激酶切割得到具有纤溶活性的重组蛋白Alfimeprase。本研究是首次报道在大肠杆菌中可溶表达Alfimeprase,为以后深入研究其功能及应用奠定了基础。     

重组人胰岛素样生长因子1的原核可溶性表达及活性鉴定

目的:原核可溶性表达人胰岛素样生长因子1(hIGF-1)并进行生物活性测定。方法:PCR扩增hIGF-1核酸序列,克隆至融合表达载体pET-DsbC中,转入大肠杆菌BL21(DE3)进行诱导、表达和纯化,对融合蛋白DsbC-hIGF-1分别进行酶切、Western印迹和生物活性测定。结果:融合蛋白DsbC-hIGF-1在原核系统内经IPTG诱导,主要以可溶性形式表达,其表达量占菌体总蛋白量的30%～35%,Western印迹和MTT法测定结果证明重组DsbC-hIGF-1蛋白具有较强的抗原活性和明显的促NIH/3T3细胞增殖作用。结论:融合蛋白DsbC-hIGF在大肠杆菌中以可溶性表达形式存在并具有类似天然hIGF-1的生物活性,这对进一步研究hIGF-1的结构和功能,开发相应的基因工程产品具有重要意义。     

抗肿瘤疫苗MAGE1-MAGE3-HSP70蛋白特性及其纯化策略的研究

目的:对MAGE1-MAGE3-HSP70(M1-M3-HSP70)融合蛋白的理化性质及其纯化策略进行初步研究,为后期的临床前试验提供数据和依据。方法:以本实验室构建的菌种(BL21(DE3)pLysS-M1-M3-HSP70)为材料,采用常规细菌培养及诱导方法进行诱导表达,用聚丙烯酰胺凝胶(SDS-PAGE)电泳、免疫印迹(Western blotting)对目的蛋白进行分析,然后确定盐析条件,使用ButylSepharose HP疏水相互作用层析以及阴离子交换(Source 30Q填料)对目的蛋白的纯化进行分析。结果:M1-M3-HSP70蛋白在大肠杆菌中表达后,目的蛋白分为两部分,一部分为包涵体形式(44.9%),一部分为可溶表达(55.1%)。对其可溶部分进行研究发现,细菌裂解后,目的蛋白存在聚合和降解现象;确定了盐析条件、洗脱缓冲液以及稳定的PH值范围,基本确定了目的蛋白的纯化工艺。结论:明确了M1-M3-HSP70融合蛋白的基本性质,确定了目的蛋白的纯化方法,为基于融合蛋白的肿瘤疫苗的进一步研究提供了参考。     

大鼠CRIP2蛋白的表达和分离纯化

目的:获得大鼠crip2基因片段,并在大肠杆菌中表达、纯化大鼠CRIP2(cysteine-rich intestinal protein 2)蛋白。方法:从大鼠主动脉组织中提取总DNA,RT-PCR扩增出相应大小的crip2 DNA片段,与pGEM-T-easy载体连接后测序;将测序正确的crip2按照BamHⅠ和HindⅢ酶切位点克隆入原核表达载体pRSET A,将连接产物转化大肠杆菌BL21,挑出阳性克隆,IPTG诱导表达重组的6×His融合蛋白,通过镍柱进行纯化。结果:PCR获得的crip2序列与GenBank报道的一致(为707 bp);重组融合蛋白在大肠杆菌BL21中以可溶形式高效表达,经SDS-PAGE和Western印迹分析,在相对分子质量为27×103处有特异的蛋白条带,经镍柱纯化后,得到了高纯度的CRIP2融合蛋白。结论:克隆了大鼠crip2基因片段,并在大肠杆菌BL21中高效表达,亲和层析纯化后获得高纯度的CRIP2融合蛋白。     

可溶性重组人组织因子(rhTF243)分泌型表达载体的构建和表达

目的:构建含有TF的胞外区和跨膜区基因的phoA-TF243分泌型表达载体,在大肠杆菌中以可溶形式表达重组人组织因子(rhTF243)。方法:从人胎盘组织中提取总RNA,以RT-PCR扩增获得目的基因,并克隆到phoA载体中,在大肠杆菌MM294中表达rhTF243,产物采用免疫亲合层析进行纯化。结果:通过低磷酸盐诱导工程菌,获得重组人组织因子(rhTF243) ,表达水平占菌体总蛋白量的16 .3 %,经免疫亲合层析纯化,产物纯度达到95 %以上,分子量为27 .4kD。结论:获得了rhTF243,具有与完整分子完全相同的凝血功能。     

Flt3配体胞外域的原核表达纯化及活性鉴定

目的:构建pET32a(+)-hFLext原核表达载体,诱导hFLext蛋白表达、纯化及活性鉴定.方法:以人淋巴细胞cDNA文库为模板,克隆hFlext,构建pET32a(+)-hFLext重组表达载体.转化大肠杆菌BL21,IPTG诱导蛋白表达,镍珠亲合层析纯化蛋白,SDS-PAGE及Western blot鉴定.细胞增殖实验检测其生物学活性.结果:成功克隆获得hFLext,并构建了pET32a(+)-hFLext重组表达载体.在大肠杆菌BL21,经1 mM IPTG 30℃诱导12 h,成功表达Trx-hFLext融合蛋白,主要以包涵体形式存在.经8M尿素变性包涵体蛋白,逐步透析复性,镍珠亲合层析纯化蛋白,SDS-PAGE及Western blot鉴定,成功获得高纯度的Trx-hFLext融合蛋白.细胞增殖实验证实其具有生物学活性,能够有效刺激脐血细胞增殖.结论:成功构建了pET32a(+)-hFLext重组表达载体,表达、纯化了具有生物学活性的Trx-hFLext融合蛋白,为造血干/祖细胞的体外扩增研究奠定了基础.     

斑马鱼TK1基因的克隆表达

目的:克隆斑马鱼TK1基因的cDNA序列,并在大肠杆菌中诱导表达,对其产物进行生物学活性鉴定。方法:采用RT-PCR和RACE方法,克隆TK1的cDNA全长序列。表达载体在大肠杆菌BL21(DE3)中进行诱导表达。表达蛋白利用镍离子柱纯化。结果:获得TK1基因的cDNA全长序列,编码一个分子量为26kD的蛋白。结论:TK1融合蛋白在28℃条件表现出比较高的生物学活性,达到0.45 U/mg。     

人泛素结合酶9的原核表达与纯化

目的:表达和纯化高纯度的人泛素结合酶9(hUBC9)。方法:将hUBC9基因克隆到原核表达载体pGEX-6p-1上并转化大肠杆菌BL21(DE3),于30℃、1mmol/LIPTG诱导4h,表达GST-hUBC9融合蛋白。用Glutathione-Sepharose4B柱分离GST-hUBC9融合蛋白,用鼻病毒3C蛋白水解酶切去GST-hUBC9融合蛋白的GST标签,再用FPLC分子筛层析法进一步纯化hUBC9。结果和结论:获得了重组表达质粒GST-hUBC9并在大肠杆菌中可溶性表达,经亲和层析、酶切、分子筛层析后获得了可溶的、高纯度的hUBC9,为进一步研究hUBC9的功能和结构奠定了基础。     

LSECtin-CRD-GST融合蛋白的原核表达、纯化及复性

目的:构建C型凝集素LSECtin主要功能结构域CRD的原核表达载体,在大肠杆菌中表达LSECtin-CRD-GST融合蛋白。方法:根据Gen Bank发布的LSECtin基因序列设计引物,利用基因重组技术将获得的LSECtin-CRDc DNA定向克隆至C端带GST蛋白标签序列的融合表达载体p GEX-6p-1中,转化大肠杆菌Origami(DE3)进行重组蛋白的诱导表达,用GST柱亲和纯化融合蛋白。结果:获得了原核表达载体p GEX-6p-1-LSECtin-CRD,诱导表达出大量相对分子质量约40×103的包涵体融合蛋白,经纯化、复性获得可溶蛋白,经Western印迹鉴定为目的蛋白。结论:获得足量的LSECtin-CRD-GST融合蛋白,为进一步研究CRD蛋白结构域的动态构象变化提供了实验材料。     

Scytovirin在大肠杆菌中的可溶性表达

目的:获得Scytovirin(SVN)蛋白及其多克隆抗体.方法:按照NCBI上公布的SVN基因序列设计合成引物,合成SVN基因,构建pET32c-SVN原核表达重组质粒,经限制性酶切分析、DNA序列测定插入片段正确;将该重组质粒转化大肠杆菌BL21(DE3),IPTG诱导重组蛋白表达;用离子交换层析法及金属亲合层析法纯化蛋白,采用Tris-Tricine系统分析;以经过纯化的蛋白为抗原免疫白兔,制备SVN多克隆抗体.结果:对表达产物进行了分离纯化,SVN纯度达到91%;用纯化的样品制备了多克隆抗体,抗血清效价为1∶102 400.结论:SVN在大肠杆菌表达系统中获得了高效可溶表达,并制备了其多克隆抗体,为进一步深入研究SVN提供了材料.     

Extracellular production of human parathyroid hormone as a thioredoxin fusion form in Escherichia coli by chemical permeabilization combined with heat treatment

A pET system encoding the fusion protein gene of thioredoxin (Trx) and human parathyroid hormone (hPTH) was introduced into Escherichia coli BL21 (DE3). Recombinant Trx-hPTH fusion protein was expressed in soluble form in the cytoplasm of the E. coli transformant. To recover Trx-hPTH from the E. coli culture efficiently, a novel tactic was developed by adding Triton X-100 into the fermentation culture at the exponential growth phase of E. coli and by heat treatment of the culture at the end of the fermentation. A concentration of 1% (v/v) Triton X-100 was added into the culture at the same time as IPTG addition after optimization. Under these conditions, addition of Triton X-100 had little effect on the cell growth, but more than 75% of the total recombinant Trx-hPTH was released into the fermentation broth. Also, a much higher volumetric yield of recombinant Trx-hPTH could be obtained with protein release compared to yield without protein release. Simultaneously, owing to the highly thermal stability of Trx-hPTH fusion protein, heat treatment of the fermentation broth at 80 degrees C for 15 min at the end of fermentation was employed for primary purification. Results demonstrated that heat treatment not only boosted further release of the recombinant Trx-hPTH fusion protein into the fermentation broth but also precipitated/denatured most of the nontarget proteins released in the broth. The tactics described herein integrated the fermentation process with subsequent recovery steps and thus provided a valuable and economical method for the production of Trx-hPTH and maybe some other Trx fusions in E. coli.     

Accurate disulfide formation in Escherichia coli: overexpression and characterization of the first domain (HF6478) of the multiple Kazal-type inhibitor LEKTI

The human hemofiltrate peptide HF6478, a putative serine proteinase inhibitor, which is part of the precursor protein LEKTI, was cloned, overexpressed, and purified. HF6478 contains two disulfide bridges with 1-4, 2-3 connectivity, sharing partial homology to Kazal-type domains and other serine proteinase inhibitors. It was expressed as thioredoxin (Trx) fusion protein, and disulfide formation occurred in the oxidative cytoplasm of Escherichia coli Origami (DE3) strain which carries a trxB(-)/gor522(-) double mutation. The soluble fusion protein was purified using metal-chelating affinity chromatography. Cleavage of the Trx fusion protein with factor Xa and subsequent purification yielded the final product in amounts sufficient for structural studies. Characterization of recombinant HF6478 was done by amino acid sequencing, mass spectrometry, capillary zone electrophoresis, and CD spectroscopy. Taking the blood filtrate peptide HF6478 as example, we present a strategy which should facilitate the expression of different extracellular proteins in the E. coli cytoplasm.     

Expression of human cardiac-specific homeobox protein in Escherichia coli

Human cardiac-specific homeobox protein cDNA (hCsx) was cloned into expression plasmid pET32a and fused with Escherichia coli thioredoxin (Trx). The Trx-Csx fusion protein was under the control of bacteriophage T7 promoter. When expressed in E. coli BL21(DE3), about half of the recombinant Trx-Csx products existed in the form of insoluble inclusion bodies. When coexpressed with human protein disulfide isomerase, more than 90% of Trx-Csx products accumulated in the soluble form in the cell lysate. The recombinant Csx fusion protein was purified by one-step metal-chelating affinity chromatography.     

重组人半乳凝集素-1的原核表达、纯化及生物活性检测

目的:在大肠杆菌中表达半乳凝集素-1(galectin-1),并进行纯化及生物活性检测。方法:将人半乳凝集素-1基因克隆至带有His融合标签的原核表达载体pQE-30上,转化大肠杆菌M15,经IPTG诱导表达,表达产物经亲和层析纯化后,进行Western印迹鉴定,并用红细胞凝集试验检测其生物学活性。结果:双酶切鉴定和核苷酸序列测定表明重组表达质粒pQE-30-Galectin-1构建正确;重组蛋白的表达量约占菌体总蛋白的50%,主要以可溶形式表达,纯化后蛋白纯度达95%以上,且具有良好的红细胞凝集活性。结论:在大肠杆菌中表达了重组人半乳凝集素-1,且具有良好的生物活性。     

Affinity purification of insoluble recombinant fusion proteins containing glutathione-S-transferase

Prokaryotic expression of polypeptides as fusion proteins with glutathione-S-transferase has recently been reported as a one-step means of purifying recombinant protein. The usefulness of the glutathione-S-transferase/glutathioneagarose system, however, is significantly limited by the frequent synthesis of recombinant proteins in insuluble form by Escherichia coli. We have found that for 5 separate fusion proteins containing glutathione-S-transferase and different domains of the large cystic fibrosis transmembrane conductance regulator, all were packaged in insoluble form by E. coli. Insolubility of these products made them inaccessible to one-step purification utilizing this scheme requires proper folding of recombinant glutathione-S-transferase to allow recognition on glutathione affinity agarose, we investigated the suitability of several alternative approaches for converting insoluble recombinant fusion proteins to a soluble form amenable to glutathione-agarose affinity purification. Low-temperature induction of fusion protein synthesis, but not incubation with anion-exchange resins, led to improved one-step purification of glutathione-S-transferase fusion proteins from E. coli cell lysate using mild, nondenaturing conditions. Solubilization in 8 mol/L urea, but not with other chaotropic agents or detergents, also allowed preparative yields of affinity-purified fusion protein. These techniques increase the usefulness of this recombinant protein purification scheme, and should be broadly applicable to diverse polypeptides synthesized as fusions with glutathione-S-transferase.     

High-level expression, purification, and characterization of the recombinant grass carp pituitary adenylate cyclase-activating polypeptide

Pituitary adenylate cyclase-activating polypeptide-38 (PACAP(38)) is a potent secretagog for growth hormone and gonadotropin in fish species. To obtain recombinant grass carp PACAP(38), its open reading frame was subcloned in pET32a(+) vector to express thioredoxin (Trx)-PACAP fusion protein in Escherichia coli BL21 (DE3). The resulting expression level of the thioredoxin-PACAP reached 36% of the total proteins, and more than 85% of fusion protein existed as soluble form. Using Ni(2+)-chelating affinity chromatography, 102 mg of Trx-PACAP(38) with a purity of 97% was obtained from 342 mg of crude proteins from a 1-liter culture of Escherichia coli. The purified Trx-PACAP specifically inhibited T98G human glioblastoma cell proliferation, but the fusion partner had no effect in this regard. Moreover, this inhibition was totally abolished by PACAP-specific antibody.     

具有抗HIV活性的突变型天花粉蛋白TCSYFF-KR的构建及原核表达

目的：构建具有抗HIV活性的突变型天花粉蛋白（TCS）,并将其在原核系统内进行表达与纯化。方法：借助计算机预测TCS分子上可能的抗原决定簇（YFF81-83和KR173-174）,并依此设计适当的突变引物;以栝楼基因组DNA为模板,利用重组PCR技术扩增双突变型TCS全长基因,经BamHI和EcoRI双酶切后与原核表达载体pRSET-A连接,转化感受态大肠杆菌DH5α,提取质粒进行酶切鉴定及测序;将所获阳性重组质粒转化感受态大肠杆菌BL21（DE3）,经IPTG诱导表达后,对表达产物进行Western印迹鉴定;用Ni-NTA亲和层析柱对所获突变型TCS蛋白进行纯化。结果：构建了突变型TCSYFY-KR,并获得了该蛋白在大肠杆菌内的可溶性高效表达;经Ni-NTA亲和层析柱纯化,产生大量均一的突变型TCS蛋白。结论：TCS的定点突变及其在原核系统内的表达,为基因工程方法改造TCS提供了一条新途径。     

Expression and characterization of transforming protein E7 from cervical cancer-associated human papillomavirus type 31

E7 protein is a major oncogenic factor of human papillomaviruses (HPVs) that plays a key role in virus-associated human cervical carcinogenesis. To determine the biochemical properties of the E7 protein of high-risk HPV type 31, the gene encoding the protein was cloned into a bacterial vector, pET-32a (+), to allow expression of HPV-31E7 as a thioredoxin (Trx) fusion protein in Escherichia coli BL21 (DE3). The resulting expression level of the fusion protein reached 15 ～ 20% of the total cell protein and more than 60% of the target proteins were in soluble form upon cultivation for 6 h at 30°C in the presence of 0.5 mM IPTG. The fusion protein Trx-HPV-31E7 was effectively purified by Ni²⁺-chelating chromatography and analyzed by SDS-PAGE and Western blotting. After release from the fusion protein by enterokinase cleavage and purification to homogeneity, the recombinant HPV-31E7 (rHPV-31E7) was investigated for in vitro interaction with the pocket protein p107, which is known to interact with the amino-terminal portion of the protein. The immunoprecipitation studies revealed strong interactions of rHPV-31E7 protein with p107, suggesting it had binding activities and retained its conformational properties.     

Improved expression and purification of the correctly folded response regulator PlnC from lactobacilli

The response regulator PlnC is part of the signal transduction system that plays a key role in the regulation of bacteriocin production in Lactobacillus plantarum C11. In this study, we wanted to express high levels of the response regulator PlnC in a soluble and native form for purification and further studies. The protein was expressed as a fusion protein (fPlnC) containing an N-terminal Flag-tag to facilitate detection and purification. When the fusion gene, fplnC, was expressed in Escherichia coli BL21, nearly all (99%) of the recombinant protein ended up inside inclusion bodies as an incorrectly folded protein. By utilizing two different Gram-positive expression systems (SIP and NICE) in L. plantarum NC8 and Lactobacillus sakei Lb790, the expression of the soluble fPlnC was significantly increased, being 20-40 times more than that in E. coli BL21. Using the N-terminal tag, the expressed protein was purified by immunoprecipitation. By DNA-binding study (EMSA), we demonstrated that the fusion protein purified from the soluble pool was correctly folded as judged by its ability to bind specifically on regulated promoters. Using our approach, we estimate that about 1 mg of fPlnC can be purified from 11 of the bacterial culture.     

Separation and purification of Escherichia coli-expressed human thymosin-α1 using affinity chromatography and high-performance liquid chromatography

In this study, a human thymosin-α1 (hTα1) fusion protein was overexpressed in Escherichia coli (E. coli). The hexahistidine-tagged hTα1 fusion protein was obtained in soluble form in cells of the engineered E. coli strain BL21 (DE3)/pET-28a-hTα1 that had been induced with isopropyl -D-1-thiogalactopyranoside (IPTG). The recombinant protein accounted for approximately 50-60% of the total protein. We then developed and validated a separation method for hTα1 from E. coli cells based on thermal denaturation, nickel-resin affinity chromatography and high-performance liquid chromatography. The purification method showed good reproducibility and was easy to operate. Purified recombinant hTα1 of high homogeneity was characterized and found to be of high purity (over 99%), as determined by high-voltage electrophoresis and high-performance liquid chromatography analysis. Isoelectric focusing analysis indicated a pI of approximately 4.0, and full wavelength screening showed an optimal absorbance wavelength at around 214nm.